DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages
Author: Hon A/Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand, August 2015.
Tuberculosis (TB) is a serious bacterial infection with Mycobacterium tuberculosis (M. tuberculosis). The active infection causes serious illness and death and can be difficult to treat. It can also spread to other people. Symptoms of an active infection can include:
Active TB often involves the lungs but can involve any part of the body including the skin (cutaneous TB).
TB screening refers to the process of examining and testing a patient that does not have any symptoms of active TB. Screening is undertaken to identify and treat latent TB so that it can be effectively treated before it becomes an active infection.
Latent TB occurs when patients carry live M. tuberculosis bacteria without knowing they are infected because their immune system has walled off the bacteria. In healthy people, TB bacteria can remain alive in the body without causing disease for many years. Latent TB does not infect other people.
If the immune system is broken down, for example, if the normal cytokine TNFα is removed by certain treatments, latent TB may become active TB.
Active or latent TB infection is not common in New Zealand and other developed countries but continues to be reported in certain population groups. Risk factors for TB infection include:
TB screening should be undertaken in people at risk of tuberculosis and in people at risk for converting undetected latent TB to active TB. For example:
After taking a history and general examination, the main TB screening tests are:
Skin testing and TB blood tests are usually positive in patients with latent TB; they demonstrate prior infection and a good level of immunity to it. The tests are also positive in patients with active TB.
The test results may require expert interpretation. Other tests may also be required, depending on symptoms.
Latent TB can be suspected on chest X-ray if any of the following features is/are present:
Patients with active TB may have cavitations or other signs on X-ray. A patient with latent TB may have a normal chest X-ray.
The tuberculin skin test or Mantoux test contains a purified protein derivative (PPD) of TB bacteria, so it is also called a PPD test. The test material does not contain live bacteria and cannot cause TB. The test is undertaken by specially trained laboratory technicians and other healthcare workers.
The test site is inspected between 2 and 3 days later. The diameter of hard skin thickening is recorded in millimetres. The test is classified as negative (no induration or less than 5 mm induration ) or abnormal (more than 5 mm induration). Abnormal tests may take weeks to subside and can leave a mark or scar.
The usual TB blood test is interferon-gamma release assay (IGRA). There are several options, including QuantiFERON Gold™. One advantage of IGRA over skin testing is that it is not positive after BCG vaccination. A disadvantage is a difficulty and expense of conducting the test accurately.
Test results may be positive (infection is likely), negative (it is unlikely), indeterminate or borderline (uncertain). Borderline reactions are more often observed in patients taking immunosuppressives, systemic steroids and antimalarial medications in patients that do not have tuberculosis. The test should be repeated at a later date, as a precaution.
Even if initially negative, TB tests should be repeated from time to time in patients who are at risk of being infected with TB and in those who are at risk of latent TB converting to active TB.
If the test is positive, the result should be evaluated by a physician. Further tests and follow-up may be appropriate.
Treatment of TB is recommended in patients with active TB and in those at risk for the conversion of latent TB to active TB, for example, if they have a chronic immunodeficiency illness or treatment with an immunosuppressive drug.
The usual treatment is either isoniazid for 6 months, rifampicin for 3 months, or a combination. Guidelines vary for different populations, and if the patient is pregnant or has liver disease (see references).
TB testing should be repeated every year or so in patients on immune suppressive medications or in other patients at significant risk of active TB.
© 2020 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.